


## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY, 1970

(51) International Patent Classification <sup>6</sup> :	A2	(11) International Publication Number:	WO 98/08546
A61K 45/06		(43) International Publication Date:	5 March 1998 (05.03.98)
(21) International Application Number:	PCT/US97/15155	(74) Agents:	STEFFE, Eric, K. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue N.W., Washington, DC 20005-3934 (US).
(22) International Filing Date:	28 August 1997 (28.08.97)	(81) Designated States:	AU, CA, IL, JP, MX, NO, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority Data:	60/024,772	28 August 1996 (28.08.96)	US
(71) Applicants:	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE [FR/FR]; 101, rue Tolbiac, F-75654 Paris Cedex (FR). CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3, rue Michel Ange, F-75794 Paris Cedex 16 (FR). UNIVERSITE LOUIS PASTEUR [FR/FR]; 4, rue Blaise Pascal, Boite postale 1032F, F-67070 Strasbourg Cedex (FR). BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206, Provinceline Road, Princeton, NJ 08543-4000 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>
(72) Inventors:	CHAMBON, Pierre; 4, rue A. Schweitzer, F-67113 Blaesheim (FR). GRONEMEYER, Hinrich; Uhlandstrasse 1A, D-77704 Oberkirch (DE). RECZEK, Peter, R.; Dept. 842, 100 Forest Avenue, Buffalo, NY 14213-1091 (US). OSTROWSKI, Jacek; Dept. 842, 100 Forest Avenue, Buffalo, NY 14213-1091 (US).		

(54) Title: THERAPEUTIC COMBINATIONS OF RAR ANTAGONISTS AND RXR AGONISTS



## (57) Abstract

The present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder by administering an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR $\alpha$  antagonist, and at least one RXR agonist. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KR	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SR	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## THERAPEUTIC COMBINATIONS OF RAR ANTAGONISTS AND RXR AGONISTS

5

## BACKGROUND OF THE INVENTION

**Field of the Invention**

The present invention relates to the fields of retinoid receptor biology and mammalian disease therapeutics. Specifically, the present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder, by 10 administering to the animal an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR $\alpha$  antagonist, and at least one RXR agonist.

**Related Art*****Retinoids***

A number of studies have demonstrated that retinoids (vitamin A derivatives) are essential 15 for normal growth, vision, tissue homeostasis, reproduction and overall survival (for reviews and references, See Sporn *et al.*, *The Retinoids*, Vols. 1 and 2, Sporn *et al.*, eds., Academic Press, Orlando, Florida (1984)). For example, retinoids have been shown to be vital to the maintenance of skin homeostasis and barrier function in mammals (Fisher, G.J., and Voorhees, J.J., *FASEB J.* 10:1002-1013 (1996)). Retinoids are also apparently crucial during embryogenesis, since 20 offspring of dams with vitamin A deficiency (VAD) exhibit a number of developmental defects (Wilson, J.G., *et al.*, *Am. J. Anat.* 92:189-217 (1953); Morriss-Kay, G.M., and Sokolova, N., *FASEB J.* 10:961-968 (1996)). With the exceptions of those on vision (Wald, G., *et al.*, *Science* 162:230-239 (1968)) and spermatogenesis in mammals (van Pelt, H.M.M., and De Rooij, D.G., *Endocrinology* 128:697-704 (1991)), most of the effects generated by VAD in animals and their 25 fetuses can be prevented and/or reversed by retinoic acid (RA) administration (Wilson, J.G., *et al.*, *Am. J. Anat.* 92:189-217 (1953); Thompson *et al.*, *Proc. Royal Soc.* 159:510-535 (1964); Morriss-Kay, G.M., and Sokolova, N., *FASEB J.* 10:961-968 (1996)). The dramatic teratogenic

effects of maternal RA administration on mammalian embryos (Shenefelt, R.E., *Teratology* 5, 103-108 (1972); Kessel, M., *Development* 115:487-501 (1992); Creech Kraft, J., In *Retinoids in Normal Development and Teratogenesis*, G.M. Morriss-Kay, ed., Oxford University Press, Oxford, UK, pp. 267-280 (1992)), and the marked effects of topical administration of retinoids 5 on embryonic development of vertebrates and limb regeneration in amphibians (Mohanty-Hejmadi *et al.*, *Nature* 355:352-353 (1992); Tabin, C.J., *Cell* 66:199-217 (1991)), have contributed to the notion that RA may have critical roles in morphogenesis and organogenesis.

### *Retinoid Receptors*

Except for those involved in visual perception (Wald, G. *et al.*, *Science* 162:230-239 10 (1968)), the molecular mechanisms underlying the highly diverse effects of retinoids have until recently remained obscure. The discovery of nuclear receptors for RA (Petkovich *et al.*, *Nature* 330:444-450 (1987); Giguère *et al.*, *Nature* 330:624-629 (1987)) has greatly advanced the understanding of how the retinoids may exert their pleiotropic effects (Leid *et al.*, *TIBS* 17:427-433 (1992); Linney, E., *Current Topics in Dev. Biol.* 27:309-350 (1992)). Since this discovery 15 it has become apparent that the genetic activities of the RA signal are mediated through two families of receptors -- the RAR family and the RXR family -- which belong to the superfamily of ligand-inducible transcriptional regulatory factors that include steroid/thyroid hormone and vitamin D<sub>3</sub> receptors (for reviews see Leid *et al.*, *TIBS* 17:427-433 (1992); Chambon, P., *Semin. Cell Biol.* 5:115-125 (1994); Chambon, P., *FASEB J.* 10:940-954 (1996); Giguere, V., 20 *Endocrinol. Rev.* 15:61-79 (1994); Mangelsdorf, D.J., and Evans, R.M., *Cell* 83:841-850 (1995); Gronemeyer, H., and Laudet, V., *Protein Profile* 2:1173-1236 (1995)).

### *RAR Receptors*

Receptors belonging to the RAR family (RAR $\alpha$ ,  $\beta$  and  $\gamma$  and their isoforms) are activated by both all-*trans*- and 9-*cis*-RA (Leid *et al.*, *TIBS* 17:427-433 (1992); Chambon, P., *Semin. Cell Biol.* 5:115-125 (1994); Dollé, P., *et al.*, *Mech. Dev.* 45:91-104 (1994); Chambon, P., *FASEB J.* 10:940-954 (1996)). Within a given species, the DNA binding (C) and the ligand binding (E) domains of the three RAR types are highly similar, whereas the C-terminal domain F and the

middle domain D exhibit no or little similarity. The amino acid sequences of the three RAR types are also notably different in their B regions, and their main isoforms ( $\alpha 1$  and  $\alpha 2$ ,  $\beta 1$  to  $\beta 4$ , and  $\gamma 1$  and  $\gamma 2$ ) further differ in their N-terminal A regions (Leid *et al.*, *TIBS* 17:427-433 (1992))

Amino acid sequence comparisons have revealed that the interspecies conservation of a given

5 RAR type is greater than the similarity found between the three RAR types within a given species (Leid *et al.*, *TIBS* 17:427-433 (1992)). This interspecies conservation is particularly striking in the N-terminal A regions of the various RAR $\alpha$ ,  $\beta$  and  $\gamma$  isoforms, whose A region amino acid sequences are quite divergent. Taken together with the distinct spatio-temporal expression patterns observed for the transcripts of each RAR and RXR type in the developing embryo and  
10 in various adult mouse tissues (Zelent, A., *et al.*, *Nature* 339:714-717 (1989); Dollé, P., *et al.*, *Nature* 342:702-705 (1989); Dollé *et al.*, *Development* 110:1133-1151 (1990); Ruberte *et al.*, *Development* 108:213-222 (1990); Ruberte *et al.*, *Development* 111:45-60 (1991); Mangelsdorf *et al.*, *Genes & Dev.* 6:329-344 (1992)), this interspecies conservation has suggested that each  
15 RAR type (and isoform) may perform unique functions. This hypothesis is further supported by the finding that the various RAR isoforms contain two transcriptional activation functions (AFs) located in the N-terminal A/B region (AF-1) and in the C-terminal E region (AF-2), which can synergistically, and to some extent differentially, activate various RA-responsive promoters (Leid *et al.*, *TIBS* 17:427-433 (1992); Nagpal, S., *et al.*, *Cell* 70:1007-1019 (1992); Nagpal, S., *et al.*, *EMBO J.* 12:2349-2360 (1993)).

20 *RXR Receptors*

Unlike the RARs, members of the retinoid X receptor family (RXR $\alpha$ ,  $\beta$  and  $\gamma$ ) are activated exclusively by 9-cis-RA (Chambon, P., *FASEB J.* 10:940-954 (1996); Chambon, P., *Semin. Cell Biol.* 5:115-125 (1994); Dollé, P., *et al.*, *Mech. Dev.* 45:91-104 (1994); Linney, E., *Current Topics in Dev. Biol.* 27:309-350 (1992); Leid *et al.*, *TIBS* 17:427-433 (1992); Kastner  
25 *et al.*, in *Vitamin A in Health and Disease*, R. Blomhoff, ed., Marcel Dekker, New York (1993)). However, the RXRs characterized to date are similar to the RARs in that the different RXR types also differ markedly in their N-terminal A/B regions (Leid *et al.*, *TIBS* 17:427-433 (1992); Leid *et al.*, *Cell* 68:377-395 (1992); Mangelsdorf *et al.*, *Genes and Dev.* 6:329-344 (1992)), and contain the same transcriptional activation functions in their N-terminal A/B region and C-terminal

E region (Leid *et al.*, *TIBS* 17:427-433 (1992); Nagpal, S., *et al.*, *Cell* 70:1007-1019 (1992); Nagpal, S., *et al.*, *EMBO J.* 12:2349-2360 (1993)).

RXR $\alpha$  and RXR $\beta$  have a widespread (possibly ubiquitous) expression pattern during mouse development and in the adult animal, being found in all fetal and adult tissues thus far examined (Mangelsdorf, D.J., *et al.*, *Genes & Devel.* 6:329-344 (1992); Dollé, P., *et al.*, *Mech. Devel.* 45:91-104 (1994); Nagata, T., *et al.*, *Gene* 142:183-189 (1994)). RXR $\gamma$  transcripts, however, appear to have a more restricted distribution, being expressed in developing skeletal muscle in the embryo (where their expression persists throughout life), in the heart (after birth), in sensory epithelia of the visual and auditory systems, in specific structures of the central nervous system, and in tissues involved in thyroid hormone homeostasis, e.g., the thyroid gland and thyrotrope cells in the pituitary (Mangelsdorf, D.J., *et al.*, *Genes & Devel.* 6:329-344 (1992); Dollé, P., *et al.*, *Mech. Devel.* 45:91-104 (1994); Sugawara, A., *et al.*, *Endocrinology* 136:1766-1774 (1995); Liu, Q., and Linney, E., *Mol. Endocrinol.* 7:651-658 (1993)).

It is currently unclear whether all the molecular properties of RXRs characterized *in vitro* are relevant for their physiological functions *in vivo*. In particular, it is unknown under what conditions these receptors act as 9-cis-RA-dependent transcriptional regulators (Chambon, P., *Semin. Cell Biol.* 5:115-125 (1994)). The knock-outs of RXR $\alpha$  and RXR $\beta$  in the mouse have provided some insight into the physiological functions of these receptors. For example, the ocular and cardiac malformations observed in RXR $\alpha^{-/-}$  fetuses (Kastner, P., *et al.*, *Cell* 78:987-1003 (1994); Sucov, H.M., *et al.*, *Genes & Devel.* 8:1007-1018 (1994)) are similar to those found in the fetal VAD syndrome, thus suggesting an important function of RXR $\alpha$  in the transduction of a retinoid signal during development. The involvement of RXRs in retinoid signaling is further supported by studies of compound RXR $\alpha$ /RAR mutants, which reveal defects that are either absent or less severe in the single mutants (Kastner, P., *et al.*, *Cell* 78:987-1003 (1994); Kastner, P., *et al.*, *Cell* 83:859-869 (1995)). Interestingly, however, knockout of RXR $\gamma$  in the mouse induces no overt deleterious effects, and RXR $\gamma^{-/-}$  homozygotes which are also RXR $\alpha^{-/-}$  or RXR $\beta^{-/-}$  exhibit no additional abnormalities beyond those seen in RXR $\alpha^{-/-}$ , RXR $\beta^{-/-}$  and fetal VAD syndrome fetuses (Krezel, W., *et al.*, *Proc. Natl. Acad. Sci. USA* 93(17):9010-9014 (1996)), suggesting that RXR $\gamma$ , despite its highly tissue-specific expression pattern in the developing embryo, is dispensable for embryonic development and postnatal life in the mouse. The

observation that live-born RXR $\gamma^{+/-}$ /RXR $\beta^{+/-}$ /RXR $\alpha^{+/-}$  mutants can grow to reach adult age (Krezel *et al.*, *Proc. Natl. Acad. Sci. USA* 93(17):9010-9014 (1996)) indicates that a single RXR $\alpha$  allele is sufficient to carry out all of the vital developmental and postnatal functions of the RXR family of receptors, particularly all of the developmental functions which depend on RARs and may 5 require RXR partnership (Dollé, P., *et al.*, *Mech. Dev.* 45:91-104 (1994); Kastner, P., *et al.*, *Cell* 83:859-869 (1995)). Furthermore, the finding that RXR $\alpha^{+/-}$ /RXR $\gamma^{+/-}$  double mutant embryos are not more affected than are single RXR $\alpha^{+/-}$  mutants (Krezel *et al.*, *Proc. Natl. Acad. Sci. USA* 93(17):9010-9014 (1996)) clearly shows that RXR $\beta$  alone can also perform some of these 10 functions. Therefore, the fact that RXR $\alpha$  alone and, to a certain extent RXR $\beta$  alone, are sufficient for the completion of a number of developmental RXR functions, clearly indicates the existence 15 of a large degree of functional redundancy amongst RXRs. In this respect, the RXR situation is different from that of RARs, since all of types of RAR double mutants displayed much broader sets of defects than single mutants (Rowe, A., *et al.*, *Develop.* 111:771-778 (1991); Lohnes, D., *et al.*, *Develop.* 120:2723-2748 (1994); Mendelsohn, C., *Develop.* 120:2749-2771 (1994)).

15            *Retinoid Binding to RAR and RXR Receptors*

The crystal structures of the ligand-binding domains (LBDs) of the RARs and RXRs have recently been elucidated (Bourget, W., *et al.*, *Nature* 375:377-382 (1995); Renaud, J.P., *et al.*, *Nature* 378:681-689 (1995); Wurtz, J.M., *et al.*, *Nature Struct. Biol.* 3:87-94 (1996)). Among the various RAR types, substantial amino acid sequence identity is observed in these domains: 20 comparison of the LBDs of RAR $\alpha$ , RAR $\beta$  and RAR $\gamma$  indicates that only three amino acid residues are variable in the ligand-binding pocket of these receptors. These residues apparently account for the fact that the various RAR types exhibit some selectivity in binding certain synthetic retinoids (Chen, J.-Y., *et al.*, *EMBO J.* 14(6):1187-1197 (1995); Renaud, J.P., *et al.*, *Nature* 378:681-689 (1995)), and consideration of these divergent residues can be used to design 25 RAR type-specific synthetic retinoids which may be agonistic or antagonistic (Chambon, P., *FASEB J.* 10:940-954 (1996)). This design approach may be extendable generally to other nuclear receptors, such as thyroid receptor  $\alpha$  (Wagner, R.L., *et al.*, *Nature* 378:690-697 (1995)), the ligand-binding pockets of which may chemically and structurally resemble those of the RARs (Chambon, P., *FASEB J.* 10:940-954 (1996)). Conversely, molecular modeling of the ligand-

binding pocket of the RXRs demonstrates that there are no overt differences in amino acid composition between RXR $\alpha$ , RXR $\beta$  and RXR $\gamma$  (Bourguet, W., et al., *Nature* 375:377-382 (1995); Wurtz, J.M., et al., *Nature Struct. Biol.* 3:87-94 (1996)), suggesting that design of type-specific synthetic ligands for the RXRs may be more difficult than for the RARs (Chambon, P., 5 *FASEB J.* 10:940-954 (1996)).

#### *Retinoid Signaling Through RAR:RXR Heterodimers*

Nuclear receptors (NRs) are members of a superfamily of ligand-inducible transcriptional regulatory factors that include receptors for steroid hormones, thyroid hormones, vitamin D3 and retinoids (Leid, M., et al., *Trends Biochem. Sci.* 17:427-433 (1992); Leid, M., et al., *Cell* 68:377-10 395 (1992); and Linney, E. *Curr. Top. Dev. Biol.*, 27:309-350 (1992)). NRs exhibit a modular structure which reflects the existence of several autonomous functional domains. Based on amino acid sequence similarity between the chicken estrogen receptor, the human estrogen and glucocorticoid receptors, and the v-erb-A oncogene (Krust, A., et al., *EMBO J.* 5:891-897 (1986)), defined six regions -- A, B, C, D, E and F -- which display different degrees of 15 evolutionary conservation amongst various members of the nuclear receptor superfamily. The highly conserved region C contains two zinc fingers and corresponds to the core of the DNA-binding domain (DBD), which is responsible for specific recognition of the cognate response elements. Region E is functionally complex, since in addition to the ligand-binding domain (LBD), it contains a ligand-dependent activation function (AF-2) and a dimerization interface. 20 An autonomous transcriptional activation function (AF-1) is present in the non-conserved N-terminal A/B regions of the steroid receptors. Interestingly, both AF-1 and AF-2 of steroid receptors exhibit differential transcriptional activation properties which appear to be both cell type and promoter context specific (Gronemeyer, H. *Annu. Rev. Genet.* 25:89-123 (1991)).

As described above, the all-*trans* (T-RA) and 9-*cis* (9C-RA) retinoic acid signals are 25 transduced by two families of nuclear receptors, RAR  $\alpha$ ,  $\beta$  and  $\gamma$  (and their isoforms) are activated by both T-RA and 9C-RA, whereas RXR  $\alpha$ ,  $\beta$  and  $\gamma$  are exclusively activated by 9C-RA (Allenby, G. et al., *Proc. Natl. Acad. Sci. USA* 90:30-34 (1993)). The three RAR types differ in their B regions, and their main isoforms ( $\alpha 1$  and  $\alpha 2$ ,  $\beta 1-4$ , and  $\gamma 1$  and  $\gamma 2$ ) have different N-

terminal A regions (Leid, M. *et al.*, *Trends Biochem. Sci.* 17:427-433 (1992)). Similarly, the RXR types differ in their A/B regions (Mangelsdorf, D.J. *et al.*, *Genes Dev.* 6:329-344 (1992)).

The E-region of RARs and RXRs has also been shown to contain a dimerization interface (Yu, V.C. *et al.*, *Curr. Opin. Biotechnol.* 3:597-602 (1992)). Most interestingly, it was demonstrated that RAR/RXR heterodimers bind much more efficiently *in vitro* than homodimers of either receptor to a number of RA response elements (RAREs) (Yu, V.C. *et al.*, *Cell* 67:1251-1266 (1991); Berrodin, T. J. *et al.*, *Mol. Endocrinol.* 6:1468-1478 (1992); Bugge, T. H. *et al.*, *EMBO J.* 11:1409-1418 (1992); Hall, R. K. *et al.*, *Mol. Cell. Biol.* 12: 5527-5535 (1992); Hallenbeck, P. L. *et al.*, *Proc. Natl. Acad. Sci. USA* 89:5572-5576 (1992); Husmann, M. *et al.*, *Biochem. Biophys. Res. Commun.* 187:1558-1564 (1992); Kliewer, S.A. *et al.*, *Nature* 355:446-449 (1992); Leid, M. *et al.*, *Cell* 68:377-395 (1992); Marks, M. S. *et al.*, *EMBO J.* 11:1419-1435 (1992); Zhang, X. K. *et al.*, *Nature* 355:441-446 (1992)). RAR and RXR heterodimers are also preferentially formed in solution *in vitro* (Yu, V.C. *et al.*, *Cell* 67:1251-1266 (1991); Leid, M. *et al.*, *Cell* 68:377-395 (1992); Marks, M. S. *et al.*, *EMBO J.* 11:1419-1435 (1992)), although the addition of 9C-RA appears to enhance the formation of RXR homodimers *in vitro* (Lehman, J. M. *et al.*, *Science* 258:1944-1946 (1992); Zhang, X. K. *et al.*, *Nature* 358:587-591 (1992b)).

It has been shown that activation of RA-responsive promoters likely occurs through RAR:RXR heterodimers rather than through homodimers (Yu, V.C. *et al.*, *Cell* 67:1251-1266 (1991); Leid *et al.*, *Cell* 68:377-395 (1992b); Durand *et al.*, *Cell* 71:73-85 (1992); Nagpal *et al.*, *Cell* 70:1007-1019 (1992); Zhang, X.K., *et al.*, *Nature* 355, 441-446 (1992); Kliewer *et al.*, *Nature* 355:446-449 (1992); Bugge *et al.*, *EMBO J.* 11:1409-1418 (1992); Marks *et al.*, *EMBO J.* 11:1419-1435 (1992); Yu, V.C. *et al.*, *Cur. Op. Biotech.* 3:597-602 (1992); Leid *et al.*, *TIBS* 17:427-433 (1992); Laudet and Stehelin, *Curr. Biol.* 2:293-295 (1992); Green, S., *Nature* 361:590-591 (1993)). The RXR portion of these heterodimers has been proposed to be silent in retinoid-induced signaling (Kurokawa, R., *et al.*, *Nature* 371:528-531 (1994); Forman, B.M., *et al.*, *Cell* 81:541-550 (1995); Mangelsdorf, D.J., and Evans, R.M., *Cell* 83:835-850 (1995)), although conflicting results have been reported on this issue (Apfel, C.M., *et al.*, *J. Biol. Chem.* 270(51):30765-30772 (1995); see Chambon, P., *FASEB J.* 10:940-954 (1996) for review). Although the results of these studies strongly suggest that RAR/RXR heterodimers are indeed functional units that transduce the RA signal *in vivo*, it is unclear whether all of the suggested

heterodimeric combinations occur *in vivo* (Chambon, P., *Semin. Cell Biol.* 5:115-125 (1994)). Thus, the basis for the highly pleiotropic effect of retinoids may reside, at least in part, in the control of different subsets of retinoid-responsive promoters by cell-specifically expressed heterodimeric combinations of RAR:RXR types (and isoforms), whose activity may be in turn 5 regulated by cell-specific levels of all-*trans*- and 9-*cis*-RA (Leid *et al.*, *TIBS* 17:427-433 (1992)).

The RXR receptors may also be involved in RA-independent signaling. For example, the observation of aberrant lipid metabolism in the Sertoli cells of RXR $\beta^{-/-}$  mutant animals suggests that functional interactions may also occur between RXR $\beta$  and the peroxisomal proliferator-activated receptor signaling pathway (WO 94/26100; Kastner, P., *et al.*, *Genes & Devel.* 10:80-92 10 (1996)).

### *Therapeutic Uses of Retinoids*

#### *Overview*

As retinoic acid is known to regulate the proliferative and differentiative capacities of several mammalian cell types (Gudas, L.J., *et al.*, *In The Retinoids*, 2nd ed., Sporn, M.B., *et al.*, 15 eds., New York: Raven Press, pp. 443-520 (1994)), retinoids are used in a variety of chemopreventive and chemotherapeutic settings. The prevention of oral, skin and head and neck cancers in patients at risk for these tumors has been reported (Hong, W. K. *et al.*, *N. Engl. J. Med.* 315:1501-1505 (1986); Hong, W. K. *et al.*, *N. Engl. J. Med.* 323:795-801 (1990); Kraemer, K. H. *et al.*, *N. Engl. J. Med.* 318:1633-1637 (1988); Bollag, W. *et al.*, *Ann. Oncol.* 3:513-526 20 (1992); Chiesa, F. *et al.*, *Eur. J. Cancer B. Oral Oncol.* 28:97-102 (1992); Costa, A. *et al.*, *Cancer Res.* 54:Suppl. 7, 2032-2037 (1994)). Retinoids have also been used to treat squamous cell carcinoma of the cervix and the skin (Verma, A. K., *Cancer Res.* 47:5097-5101 (1987); Lippman S. M. *et al.*, *J. Natl Cancer Inst.* 84:235-241 (1992); Lippman S. M. *et al.*, *J. Natl Cancer Inst.* 84:241-245 (1992)) and Kaposi's sarcoma (Bonhomme, L. *et al.*, *Ann. Oncol.* 2:234-25 235 (1991)), and have found significant use in the therapy of acute promyelocytic leukemia (Huang, M.E. *et al.*, *Blood* 72:567-572 (1988); Castaigne, S. *et al.*, *Blood* 76:1704-1709 (1990); Chomienne, C. *et al.*, *Blood* 76:1710-1717 (1990); Chomienne, C. *et al.*, *J. Clin. Invest.* 88:2150-2154 (1991); Chen Z. *et al.*, *Leukemia* 5:288-292 (1991); Lo Coco, F. *et al.*, *Blood* 77:1657-1659

(1991); Warrell, R. P., *et al.*, *N. Engl. J. Med.* 324:1385-1393 (1991); Chomienne, C., *et al.*, *FASEB J.* 10:1025-1030 (1996)).

*Acute Promyelocytic Leukemia (APL)*

A balanced chromosomal translocation, t(15;17), has been identified in most acute 5 promyelocytic leukemia (APL) cells (Larson, A.R., *et al.*, *Am. J. Med.* 76:827-841 (1984)). The breakpoint for this translocation occurs within the second intron of the RAR $\alpha$  gene (Alcalay, M.D., *et al.*, *Proc. Natl. Acad. Sci. USA* 88:1977-1981 (1991); Chang, K.S., *et al.*, *Leukemia* 5:200-204 (1991); Chen, S., *et al.*, *Blood* 78:2696-2701 (1991) and within two loci of the gene encoding the putative zinc finger transcription factor PML (Goddard, A., *et al.*, *Science* 10 254:1371-1374 (1991)). This reciprocal t(15;17) translocation leads to the generation of a PML-RAR $\alpha$  fusion protein which is co-expressed with PML and RAR $\alpha$  in APL cells (for reviews and references, see Warrell, R.P., *et al.*, *N. Engl. J. Med.* 329:177-189 (1993); Grignani, F., *et al.*, *Blood* 83:10-25 (1994); Lavau, C., and Dejean, A., *Leukemia* 8:1615-1621 (1994); de Thé, H., *FASEB J.* 10:955-960 (1996)). The PML-RAR $\alpha$  fusion is apparently responsible for the 15 differentiation block at the promyelocytic stage, since (i) it is observed in nearly all APL patients (Warrell, R.P., *et al.*, *N. Engl. J. Med.* 329:177-189 (1993); Grignani, F., *et al.*, *Blood* 83:10-25 (1994); Lavau, C., and Dejean, A., *Leukemia* 8:1615-1621 (1994)), (ii) it inhibits myeloid differentiation when overexpressed in U937 or HL60 myeloblastic leukemia cells (Grignani, F., *et al.*, *Cell* 74:423-431 (1993)), and (iii) complete clinical remission due to differentiation of the 20 leukemic cells to mature granulocytes upon treatment with all-trans retinoic acid (T-RA) is tightly linked to PML-RAR $\alpha$  expression (Warrell, R.P., *et al.*, *N. Engl. J. Med.* 324:1385-1393 (1991); Lo Coco, R., *et al.*, *Blood* 77:1657-1659 (1991); Chomienne, C., *et al.*, *FASEB J.* 10:1025-1030 (1996)). Multiple studies have addressed the possible impact of PML-RAR $\alpha$  fusion protein formation on cell proliferation (Mu, X.M., *et al.*, *Mol. Cell. Biol.* 14:6858-6867 (1994)) and 25 apoptosis (Grignani, F., *et al.*, *Cell* 74:423-431 (1993)), AP1 transrepression (Doucas, V., *et al.*, *Proc. Natl. Acad. Sci. USA* 90:9345-9349 (1993)), and vitamin D3 signaling (Perez, A., *et al.*, *EMBO J.* 12:3171-3182 (1993)), but the mechanism(s) by which PML-RAR $\alpha$  blocks myeloid cell maturation has remained elusive. Consistent with the aberrant nuclear compartmentalization of PML-RAR $\alpha$ , which adopts the "PML-type" location upon RA treatment (Dyck, J.A., *et al.*, *Cell*

76:333-343 (1994); Weis, K., *et al.*, *Cell* 76:345-358 (1994); Koken, M.H., *et al.*, *EMBO J.* 13:1073-1083 (1994)), the currently prevailing hypothesis is that PML-RAR $\alpha$  possesses altered transcriptional properties compared to PML or RAR $\alpha$  and/or may act in a dominant-negative manner (Perez, A., *et al.*, *EMBO J.* 12:3171-3182 (1993); de Thé, H., *et al.*, *Cell* 66:675-684  
5 (1991); Kastner, P., *et al.*, *EMBO J.* 11:629-642 (1992)).

#### SUMMARY OF THE INVENTION

By the invention, a method is provided for treating an animal, preferably a human, suffering from or predisposed to a physical disorder. The method comprises administering to the animal an effective amount of a composition comprising at least one RAR antagonist, preferably 10 an RAR $\alpha$  antagonist, and most preferably Compound A or Compound B, and at least one RXR agonist, most preferably SR11237. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists. Physical disorders treatable by the 15 method of the present invention include cancers (preferably a skin cancer, an oral cavity cancer, a lung cancer, a mammary gland cancer, a prostatic cancer, a bladder cancer, a liver cancer, a pancreatic cancer, a cervical cancer, an ovarian cancer, a head and neck cancer, a colon cancer, a germ cell cancer such as a teratocarcinoma or a leukemia, and most preferably acute promyelocytic leukemia), a skin disorder (preferably psoriasis, actinic keratosis, acne, ichthyosis, 20 photoaging or corticosteroid-induced skin atrophy), rheumatoid arthritis and a premalignant lesion.

The invention also provides pharmaceutical compositions comprising at least one RAR antagonist which is preferably an RAR $\alpha$  antagonist and most preferably Compound A or Compound B, at least one RXR agonist which is most preferably SR11237, and a 25 pharmaceutically acceptable carrier or excipient therefor. The invention further encompasses the use of these pharmaceutical compositions in treating an animal, preferably a human, that is suffering from or is predisposed to a physical disorder. Physical disorders treatable using the pharmaceutical compositions of the present invention include those described above.

Other preferred embodiments of the present invention will be apparent to one of ordinary skill in light of the following drawings and description of the invention, and of the claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**FIGURE 1.** Summary of agonistic and antagonistic activities of the various BMS synthetic retinoids. "+" indicates agonistic for the given receptor, "(+)" weakly agonistic, "-" antagonistic and "0" no activity.

**FIGURE 2.** False color representation of single photon camera-analysis of retinoid-induced luciferase activity originating in HeLa reporter cells treated with RAR-specific ligands alone (lane a), or with 10 nM all-trans-RA (lane b).

**FIGURE 3.** Synergy between RAR $\alpha$  agonists or antagonists and RXR agonists for the induction of NB4 cell differentiation. Photomicrographs of cells stained with nitroblue tetrazolium (a-d) or immunofluorescence photomicrographs of cells stained with anti-PML antisera (e-h) after treatment for 4 days with ethanol or the indicated retinoid(s).

**FIGURE 4.** Synergy between RAR $\alpha$  agonists or antagonists and RXR agonists for the induction of NB4 cell apoptosis. Effects of retinoids on cell cycle distribution and appearance of "sub-2N" apoptotic cells and particles, as revealed by flow cytometric analysis. The horizontal axis in each histogram indicates the integrated fluorescence intensity and the vertical axis indicates number of particles. Approximately 20,000 particles are represented in each histogram. Histograms indicating the number of cells containing a 2N, 4N or intermediate quantity of DNA for untreated NB4 cells (a), cells treated with 1 mM T-RA for 4, 6 or 8 days (b-d), 1 nM Am80 for 4 or 8 days (e, f), or the combination of 100 nM of Compound A and 100 nM of SR11237 for 4 or 8 days (g, h)

**FIGURE 5.** Retinoid induction of apoptosis in NB4 cells. Photomicrograph of an ethidium bromide-stained agarose gel in a DNA fragmentation assay, performed with cells grown in the

absence (lanes 2-4) or presence (lanes 5-13) of the indicated retinoids at the following concentrations: T-RA, 100 nM; Am80, 1 nM; SR11237, 100 nM; Compound A, 10 nM (lanes 9 and 10) and 100 nM (lanes 12 and 13).

**FIGURE 6.** Photographs of sequencing gels demonstrating synergism of RAR $\alpha$  and RXR. Cells  
5 were treated with agonists as indicated, then processed as described below for ligation-mediated  
PCR (a, b) or reverse transcriptase PCR (c) and resolved on a sequencing gel. (a) NB4 cells,  
autoradiogram; (b) P19 cells, autoradiogram; (c) NB4 cells, ethidium bromide-stained gel (RNA  
transcripts of the  $\beta$ -actin gene were used as control).

#### DETAILED DESCRIPTION OF THE INVENTION


##### 10    **Synthesis of RAR and RXR Agonists and Antagonists**

The agents to be used in the methods of the present invention can be, but are not limited to, peptides, carbohydrates, steroids and vitamin derivatives, which may each be natural or synthetic (prepared, for example, using methods of synthetic organic and inorganic chemistry that are well-known in the art). According to the invention, the agents can be selected and screened  
15 at random. For random screening, agents such as peptides, carbohydrates, steroids or vitamin derivatives (e.g., derivatives of RA) are selected at random and are assayed, using direct or indirect methods that are routine in the art, for their ability to bind to a RAR or RXR receptor or a functional retinoid RAR:RXR receptor heterodimer. For example, candidate RAR agonists according to the present invention include synthetic retinoids such as Am580, Compound 1 and  
20 Compound 2 (the structures of which are disclosed in Ostrowski *et al.*, *Proc. Natl. Acad. Sci. USA* 92:1812-1816 (1995), which is incorporated by reference herein in its entirety) and Am80 (Roy *et al.*, *Mol. Cell. Biol.* 15(12):6481-6487 (1995), which is incorporated by reference herein in its entirety). Candidate RXR agonists according to the present invention include synthetic retinoids such as SR11237 (the structure of which is disclosed in Lehman, J.M., *et al.*, *Science*  
25 258:1944-1946 (1992), which is incorporated herein in its entirety). Candidate RAR antagonists include, but are not limited to, those described previously (Chen *et al.*, *EMBO J.* 14:1187-1197


(1995); Roy *et al.*, *Mol. Cell. Biol.* 15(12):6481-6487 (1995); Chen *et al.*, *EMBO J.* 14:1187-1197 (1995), each of which is incorporated by reference herein in their entireties), and Compound A and Compound B as described in detail below.

Thus, methods are known in the art for developing candidate RAR antagonists and RXR agonists, for screening as described below, to be used according to the present invention. Specifically, the invention can be carried out with the RAR antagonist compounds designated herein as "Compound A" and "Compound B," which respectively have the following structures:

**Compound A:**



**10 Compound B:**



These compounds may be prepared as described in U.S. Patent No. 5,559,248, which is incorporated herein by reference in its entirety. Other useful RAR antagonists are described in, for example, Eyrolles *et al.*, *Med. Chem. Res.* 2:361-367 (1992) and Apfel *et al.*, *Proc. Natl. Acad. Sci. USA* 89:7129-7133 (1992), which are incorporated by reference herein in their entireties. The invention can also be carried out with the RXR agonist LG1069, the structure and preparation of which are described in Boehm *et al.*, *J. Med. Chem.* 37:2930-2941 (1994), which

is incorporated by reference herein in its entirety. Other useful RXR agonists are described in, for example, Lehmann *et al.*, *Science* 258:1944-1946 (1992), which is incorporated by reference herein in its entirety. Other RAR antagonists and RXR agonists suitable for use in the present invention may be prepared by the above-cited methods and others routine to those of ordinary skill in the art.

### Screening Methods

A number of methods for screening candidate RAR antagonists and RXR agonists, generated by rational design or computer modeling as described above, are well-known in the art, and will allow one of ordinary skill to determine if a compound is useful in the methods of the present invention. For example, in Chen *et al.*, *EMBO J.* 14(6):1187-1197 (1995), three 'reporter' cell lines have been used to characterize a number of RAR $\alpha$ -, RAR $\beta$ -, or RAR $\gamma$ -specific dissociating synthetic retinoids that selectively induce the AF-2 activation function present in the LBD of RAR $\beta$  ( $\beta$ AF-2) (Chen, J.-Y., *et al.*, *EMBO J.* 14(6):1187-1197 (1995)). These cell lines stably express chimeric proteins containing the DNA binding domain of the yeast transactivator GAL4 fused to the EF regions (which contain the LBD and the AF-2 activation function) of RAR $\alpha$  (GAL-RAR $\alpha$ ), RAR $\beta$  (GAL-RAR $\beta$ ) or RAR $\gamma$  (GAL-RAR $\gamma$ ), and a luciferase reporter gene driven by a pentamer of the GAL4 recognition sequence ('17m') in front of the  $\beta$ -globin promoter (17m)5-GAL-Luc). In these cell lines, the RAR ligands thus induce luciferase activity that can be measured in the intact cells using a single-photon-counting camera. This reporter system is insensitive to endogenous receptors which cannot recognize the GAL4 binding site. Using analogous screening assays, these synthetic retinoids, like RA, have been reported to inhibit the anchorage-independent growth of oncogene-transformed 3T3 cells, while the promoter of the human interleukin-6 (IL-6) gene, whose product is involved in the regulation of hematopoiesis, immune responses and inflammation (Kishimoto, T. *et al.*, *Science* 258:593-597 (1992)), has been shown to be induced by RA but not by the synthetic dissociating retinoids which repressed its activity. In a similar manner, RXR agonists have been identified using cell lines that express a RXR receptor linked to a TREpal-tk reporter gene which is activated by both RAR-RXR heterodimers and RXR homodimers (Lehmann, J.M., *et al.*, *Science* 258:1944-1946 (1992)).

Thus, reporter cell lines that are easily constructed, by methods routine to one of ordinary skill, may be used to distinguish not only the specific RAR or RXR types to which a candidate ligand will bind, but also whether that binding induces an activating (*i.e.*, agonistic) or repressive (*i.e.*, antagonistic) effect. Although the above-referenced reporter cell lines comprised the luciferase

5 or thymidine kinase genes as reporters, other reporters such as *Neo*, CAT,  $\beta$ -galactosidase or Green Fluorescent Protein are well known in the art and may be used in a similar fashion to carry out the present invention. For example, references disclosing reporter plasmids containing a reporter gene and expression vectors encoding a LBD of a nuclear receptor include Meyer *et al.*, *Cell* 57:433-442 (1989); Meyer *et al.*, *EMBO J.* 9(12):3923-3932 (1990); Tasset *et al.*, *Cell*

10 62:1177-1187 (1990); Gronemeyer, H., and Laudet, V., *Protein Profile* 2:1173-1308 (1995), Webster *et al.*, *Cell* 54:199-207 (1988); Strähle *et al.*, *EMBO J.* 7:3389-3395 (1988); Seipel *et al.*, *EMBO J.* 11:4961-4968 (1992); and Nagpal *et al.*, *EMBO J.* 12:2349-2360 (1993).

Other routine assays have been used to screen compounds for their agonistic or antagonistic properties on functions of other nuclear receptors, such as steroid receptors. For

15 example, a transient expression/gel retardation system has been used to study the effects of the synthetic steroids RU486 and R5020 on glucocorticoid and progesterone receptor function (Meyer, M-E., *et al.*, *EMBO J.* 9(12): 3923-3932 (1990)). Similar assays have been used to show that tamoxifen competitively inhibits estradiol-induced ERAP160 binding to the estrogen receptor, suggesting a mechanism for its growth-inhibitory effects in breast cancer (Halachimi, S., *et al.*,

20 *Science* 264:1455-1458 (1994)). Since the RAR and RXR receptors are apparently structurally similar to other nuclear receptors such as the steroid receptors (as reviewed in Chambon, P., *FASEB J.* 10:940-954 (1996)), routine assays of this type may be useful in assessing compounds for their agonistic or antagonistic activities on RAR or RXR receptors.

As an alternative routine method, the effect of a candidate agonist or antagonist on the

25 binding of the ligand-dependent AF-2 modulator TIF1 to a RAR or RXR LBD can be studied using glutathione-S-transferase (GST) interaction assays by tagging the LBDs with GST as described in detail in Le Douarin *et al.*, *EMBO J* 14:2020-2033 (1995).

In another screening assay, transgenic mice and cell lines that are altered in their expression of one or more RAR or RXR receptors may be made as described previously (Krezel,

30 W., *et al.*, *Proc. Natl. Acad. Sci. USA* 93(17):9010-9014 (1996)) and may be used to identify

agonists and antagonists of specific members of the RAR/RXR class of receptors using methods described previously (WO 94/26100). In such an assay, the agent which is to be tested will be incubated with one or more of the transgenic cell lines or mice or tissues derived therefrom. The level of binding of the agent is then determined, or the effect the agent has on development or  
5 gene expression is monitored, by techniques that are routine to those of ordinary skill. As used herein, the term "incubate" is defined as contacting the compound or agent under investigation with the appropriate cell or tissue, or administering the agent or compound to the appropriate mouse, via any one of the well-known routes of administration including enteral, intravenous, subcutaneous, and intramuscular.

10 Other assays, such as those described in detail below in Examples 1 and 2, may also be used to determine the agonistic or antagonistic effects of RAR and RXR ligands. For example, certain agonistic retinoids will induce the association of endogenous PML/PML-RAR $\alpha$  fusion protein with nuclear bodies in cells from APL patients (Dyck, J.A., et al., *Cell* 76:333-343 (1994); Weis, K., et al., *Cell* 76:345-356 (1994); Koken, M.H.M., et al., *EMBO J.* 13(5):1073-1083  
15 (1994)) or in related established cell lines such as NB4 (Lanotte, M., et al., *Blood* 77(5):1080-1086 (1991)). These effects of RAR or RXR agonists or antagonists may be determined, for example, by various immunological techniques such as immunofluorescent or immunoelectron microscopy, using antibodies specific for PML, RAR and/or PML-RAR $\alpha$  fusion proteins. RAR or RXR agonists or antagonists may also be identified by their abilities to induce the *in vitro*  
20 differentiation (maturation) of certain established cell lines such as HL-60 myeloblastic leukemia cells (Nagy, L., et al., *Mol. Cell. Biol.* 15(7):3540-3551 (1995)), NB4 promyelocytic cells (Lanotte, M., et al., *Blood* 77(5):1080-1086 (1991), P19 or F9 embryonic carcinoma cells (Roy, B., et al., *Mol. Cell. Biol.* 15(12):6481-6487 (1995); Horn, V., et al., *FASEB J.* 10:1071-1077 (1996)), or ras-transformed 3T3 cells (Chen et al., *EMBO J.* 14(6):1187-1197 (1995)). Ligand-  
25 induced differentiation in these and other cell lines may be determined by assaying ligand-treated or -untreated cells for the expression of a variety of well-known markers of differentiation as generally described in the above references.

Similarly, the candidate antagonists or agonists may be screened by measuring their abilities to induce apoptosis (programmed cell death) in, for example, HL-60 cells (Nagy, L., et  
30 al., *Mol. Cell. Biol.* 15(7):3540-3551 (1995)) or P19 cells (Horn, V., et al., *FASEB J.* 10:1071-

1077 (1996)), or in other primary cells or established cell lines. Apoptosis is typically assessed by measurement of ligand-induced DNA fragmentation, which is accomplished by methods such as gel electrophoresis (appearance of smaller molecular weight bands), microscopy (changes in plasma membrane morphology such as formation of surface protruberances ("blebbing") or in nuclear morphology such as pycnosis or fragmentation) or expression of the putative apoptosis suppressive protein BCL-2 (decreased in apoptotic cells); for general methods and discussions of these assays as they pertain to RAR and RXR biology, see Nagy, L., *et al.*, *Mol. Cell. Biol.* 15(7):3540-3551 (1995); Horn, V., *et al.*, *FASEB J.* 10:1071-1077 (1996)). Other methods for assaying ligand-induced apoptosis in primary cells and established cell lines, such as flow cytometry or particle analysis (appearance of smaller particles with different light scatter and/or DNA content profiles), are well-known in the art (Telford, W.G., *et al.*, *J. Immunol. Meth.* 172(1):1-16 (1994); Campana, D., *et al.*, *Cytometry* 18(2):68-74 (1994); Sgonc, R., and Wick, G., *Int. Arch. Allergy Immunol.* 105(4):327-332 (1994); Fraker, P.J., *et al.*, *Meth. Cell Biol.* 46:57-76 (1995); Sherwood, S.W., and Schimke, R.T., *Meth. Cell Biol.* 46:77-97 (1995); 10 Carbonari, M., *et al.*, *Cytometry* 22(3):161-167 (1995); Mastrangelo, A.J., and Betenbaugh, M.J., *Curr. Opin. Biotechnol.* 6(2):198-202 (1995)). Finally, screening of agonists or antagonists may be accomplished by an assay known as "in vivo footprinting" (Mueller, P.R., and Wold, B., *Science* 246:780-786 (1989); Garrity, P.A., and Wold, B.J., *Proc. Natl. Acad. Sci. USA* 89:1021-1025 (1992)), as described in more detail below in Examples 1 and 2, which has proven useful for 15 analysis of RA-induced transcription of RAR $\beta$ 2 (Dey, A., *et al.*, *Mol. Cell. Biol.* 14(12):8191-8201 (1994)).

Other methods for determining the agonistic or antagonistic activities of a candidate ligand which are routine in the art may also be used in carrying out the present invention. In performing such assays, one skilled in the art will be able to determine which RAR or RXR receptor type an agent binds to, what specific receptor(s) are utilized by a given compound, and whether the agent is an agonist or antagonist of the given receptor(s).

### Clinical Indications

Thus, methods for identifying, synthesizing and screening RAR antagonists and RXR agonists are well-known in the art. These ligands may then be used according to the present invention in the treatment of a variety of physical disorders in animals, particularly mammals including humans. As described above, retinoic acid is known to regulate the proliferative and differentiative capacities of several mammalian cell types (Gudas, L.J. *et al.* (1994) In Sporn, M.B., Roberts, A.B. and Goodman, D.S.(eds), *The Retinoids*. 2nd edition, Raven Press, New York, pp. 443-520). Retinoids have thus been used in a number of chemopreventive and chemotherapeutic regimens. Included among these clinical approaches are the prevention and/or treatment of a variety of cancers and premalignant lesions thereof, such as those of the oral cavity, skin (including squamous cell carcinoma, melanoma and Kaposi's sarcoma), head and neck, cervix, ovary, lung, mammary gland, bladder, prostate, liver and pancreas (Hong, W.K., *et al.*, *N. Engl. J. Med.* 315:1501-1505 (1986); Verma, A. K., *Cancer Res.* 47:5097-5101 (1987); Hong, W.K., *et al.*, *N. Engl. J. Med.* 323:795-801 (1990); Kraemer, K.H., *et al.*, *N. Engl. J. Med.* 318:1633-1637 (1988); Bonhomme, L., *et al.*, *Ann. Oncol.* 2:234-235 (1991); Bollag, W., *et al.*, *Ann. Oncol.* 3:513-526 (1992); Chiesa, F., *et al.*, *Eur. J. Cancer B. Oral Oncol.* 28:97-102 (1992); Lippman, S.M., *et al.*, *J. Natl Cancer Inst.* 84:235-241 (1992); Lippman, S.M., *et al.*, *J. Natl Cancer Inst.* 84:241-245 (1992); Costa, A., *et al.*, *Cancer Res.* 54(Suppl. 7): 2032-2037 (1994); de Thé, H., *FASEB J.* 10:955-960 (1996); Lotan, R., *FASEB J.* 10:1031-1039 (1996); Bérard, J., *et al.*, *FASEB J.* 10:1091-1097 (1996)). More specifically, retinoids have been used to treat patients afflicted with certain leukemias, particularly acute promyelocytic leukemia (Huang, M.E., *et al.*, *Blood* 72:567-572 (1988); Castaigne, S., *et al.*, *Blood* 76:1704-1709 (1990); Chomienne, C., *et al.*, *Blood* 76:1710-1717 (1990); Chomienne, C., *et al.*, *J. Clin. Invest.* 88:2150-2154 (1991); Chen, Z., *et al.*, *Leukemia* 5:288-292 (1991); Lo Coco, F., *et al.*, *Blood* 77:165701659 (1991); Warrell, R. P., *et al.*, *N. Engl. J. Med.* 324:1385-1393 (1991); Chomienne, C., *et al.*, *FASEB J.* 10:1025-1030 (1996)) Retinoids have also proven effective in the treatment of certain skin disorders such as psoriasis, acne, ichthyosis, photoaging and corticosteroid-induced skin atrophy such as that which may accompany the topical use of

corticosteroids in treating inflammation of the skin (Fisher, G.J., and Voorhees, J.J., *FASEB J.* 10: 1002-1013 (1996)).

Thus, the combinations of RAR antagonists and RXR agonists of the present invention may be used in the treatment of an animal, preferably a mammal including a human, that is suffering from or is predisposed to a variety of physical disorders. As used herein, an animal that is "predisposed to" a physical disorder is defined as an animal that does not exhibit a plurality of overt physical symptoms of the disorder but that is genetically, physiologically or otherwise at risk for developing the disorder. The combinations of RAR antagonists and RXR agonists may thus be used prophylactically as chemopreventive agents for such disorders. In treating the animal with the combinations of the present invention, the RXR agonist may be administered to the animal prior to, concurrently with, or following administration of the RAR antagonist.

Physical disorders treatable with the combinations and methods of the present invention include a variety of cancers, such as skin cancer (including melanoma and Kaposi's Sarcoma), oral cavity cancer, lung cancer, mammary gland cancer, prostatic cancer, bladder cancer, liver cancer, pancreatic cancer, cervical cancer, ovarian cancer, head and neck cancer, colon cancer, germ cell cancer (including teratocarcinoma) and leukemia, most preferably acute promyelocytic leukemia. Other physical disorders treatable with the combinations and methods of the present invention include skin disorders such as psoriasis, actinic keratosis, acne, ichthyosis, photoaging and corticosteroid-induced skin atrophy, and rheumatoid arthritis. The compositions and methods of the present invention may also be used in the prevention of disease progression, such as in chemoprevention of the progression of a premalignant lesion to a malignant lesion. The compositions and methods of the present invention may also be used to treat an animal suffering from, or predisposed to, other physical disorders that respond to treatment with retinoids.

#### **Formulation and Methods of Administration**

As indicated above, RAR- and RXR-selective ligands are known to elicit a wide array of cellular responses, several of which have clinical applications in treating a patient. The term "patient" as used herein is defined as an animal, preferably a mammal, including a human. By the invention, the dose of one or more RAR antagonists can be significantly reduced when co-

administered with at least one RXR agonist. As used herein, "an effective amount of a RAR (or RXR) antagonist" is defined as an amount effective to elicit a cellular response in cells which express a RAR (or RXR) receptor. Example clinical therapies which involve administering compositions comprising at least one RAR antagonist and at least one RXR agonist to a patient  
5 are discussed in more detail below.

Combinations of RAR agonists and RXR agonists with potential use in human therapy are known in the art (Lehmann, J.M., *et al.*, *Science* 258:1944-1946 (1992); Durand, B., *et al.*, *EMBO J.* 13:5370-5382 (1994); Lotan, R., *et al.*, *Cancer Res.* 55:232-236 (1995); Roy, B., *et al.*, *Mol. Cell. Biol.* 15(12):6481-6487 (1995); Horn, V., *et al.*, *FASEB J.* 10:1071-1077 (1996))  
10 None of these previous disclosures, however, described or predicted the unexpected finding of the current invention that combinations of RAR *antagonists* with RXR agonists are useful in treating a variety of physical disorders.

Pharmaceutical compositions are thus provided comprising at least one RAR antagonist (such as those described above), at least one RXR agonist (such as those described above), and  
15 a pharmaceutically acceptable carrier or excipient, which may be administered orally, rectally, parenterally, intrasystemically, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), buccally, or as an oral or nasal spray. Importantly, by co-administering a RAR antagonist and a RXR agonist, clinical side effects can be reduced by using lower doses of both the RAR antagonist and the RXR agonist. As indicated, it will be understood  
20 that the RXR agonist can be "co-administered" either before, after, or simultaneously with the RAR antagonist, depending on the exigencies of a particular therapeutic application. By "pharmaceutically acceptable carrier" is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal,  
25 intrasternal, subcutaneous and intraarticular injection and infusion.

Pharmaceutical compositions of the present invention for parenteral injection can comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents,  
30 solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol,

polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

5       The compositions of the present invention may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the  
10      injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drugs, it is desirable to slow the absorption from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate  
15      of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to  
20      polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-  
25      retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compounds are mixed with at least one item  
30      pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate

and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, 5 e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise 10 buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hardfilled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared 15 with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

20 The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, 25 water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters,

5 microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

Topical administration includes administration to the skin or mucosa, including surfaces of the lung and eye. Compositions for topical administration, including those for inhalation, may be prepared as a dry powder which may be pressurized or non-pressurized. In nonpressurized

10 powder compositions, the active ingredients in finely divided form may be used in admixture with a larger-sized pharmaceutically acceptable inert carrier comprising particles having a size, for example, of up to 100 µm in diameter. Suitable inert carriers include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 µm.

15 Alternatively, the composition may be pressurized and contain a compressed gas, such as nitrogen or a liquefied gas propellant. The liquefied propellant medium and indeed the total composition is preferably such that the active ingredients do not dissolve therein to any substantial extent. The pressurized composition may also contain a surface active agent. The surface active agent may be a liquid or solid non-ionic surface active agent or may be a solid anionic surface

20 active agent. It is preferred to use the solid anionic surface active agent in the form of a sodium salt.

A further form of topical administration is to the eye. The RAR antagonist(s) and RXR agonist(s) are delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the compounds are maintained in contact with the ocular surface for a sufficient time period to allow

25 the compounds to penetrate the corneal and internal regions of the eye, as for example the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera. The pharmaceutically acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating material.

Compositions for rectal or vaginal administration are preferably suppositories which can

30 be prepared by mixing the RAR antagonist(s) and RXR agonist(s) with suitable non-irritating

excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the drugs.

The compositions of the present invention can also be administered in the form of 5 liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the RAR antagonist(s) and RXR agonist(s), stabilizers, preservatives, 10 excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art (see, for example, Prescott, Ed., *Meth. Cell Biol.* 14:pp. 33 *et seq* (1976)).

### Dosaging

By the invention, a RXR agonist can be administered *in vitro*, *ex vivo* or *in vivo* to cells 15 to enhance the cellular response to a RAR antagonist. One of ordinary skill will appreciate that effective amounts of a RAR antagonist and a RXR agonist can be determined empirically and may be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form. The RAR antagonist(s) and RXR agonist(s) may be administered to a patient in need thereof as pharmaceutical compositions in combination with one or more pharmaceutically 20 acceptable excipients. It will be understood that, when administered to a human patient, the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgement. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the type and degree of the cellular response to be achieved; activity of the specific RAR antagonist 25 and RXR agonist employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the RAR antagonist and/or RXR agonist; the duration of the treatment; drugs used in combination or coincidental with the specific RAR antagonist and/or RXR agonist; and like

factors well known in the medical arts. For example, it is well within the skill of the art to start doses of RAR antagonists and/or RXR agonists at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosages until the desired effect is achieved.

For example, satisfactory results are obtained by oral administration of a RAR antagonist  
5 and a RXR agonist at dosages on the order of from 0.05 to 10 mg/kg/day, preferably 0.1 to 7.5 mg/kg/day, more preferably 0.1 to 2 mg/kg/day, administered once or, in divided doses, 2 to 4 times per day. On administration parenterally, for example by i.v. drip or infusion, dosages on the order of from 0.01 to 5 mg/kg/day, preferably 0.05 to 1.0 mg/kg/day and more preferably 0.1 to 1.0 mg/kg/day can be used. Suitable daily dosages for patients are thus on the order of from 2.5  
10 to 500 mg p.o., preferably 5 to 250 mg p.o., more preferably 5 to 100 mg p.o., or on the order of from 0.5 to 250 mg i.v., preferably 2.5 to 125 mg i.v. and more preferably 2.5 to 50 mg i.v. Dosaging of the RAR antagonist may be arranged as described in EP 0 661 259 A1, which is incorporated herein by reference in its entirety.

Dosaging may also be arranged in a patient specific manner to provide a predetermined  
15 concentration of a RAR antagonist and/or RXR agonist in the blood, as determined by techniques accepted and routine in the art (HPLC is preferred). Thus patient dosaging may be adjusted to achieve regular on-going blood levels, as measured by HPLC, on the order of from 50 to 1000 ng/ml, preferably 150 to 500 ng/ml.

It will be readily apparent to one of ordinary skill in the relevant arts that other suitable  
20 modifications and adaptations to the methods and applications described herein are obvious and may be made without departing from the scope of the invention or any embodiment thereof. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting of the invention.

**Examples****Materials and Methods**

The following materials and methods were generally used in all Examples unless otherwise noted.

5        *Determination of agonistic/antagonistic activities of RAR-specific ligands.* HeLa reporter cell lines containing a retinoid-inducible luciferase reporter gene (17m)5-globin-Luc in the stably transfected reporter constructs GAL-RAR $\alpha$ , GAL-RAR $\beta$  or GAL-RAR $\gamma$  were constructed and used as described previously (Chen, J.Y., et al., *EMBO J.* 14:1187-1197 (1995)). Cells were treated with RAR-specific ligands, and luciferase-induced bioluminescence was  
10 monitored *in vivo* using a single-photon-counting camera (Hamamatsu) by seeding equal amounts of cells in 24-well tissue culture plates and incubating them with increasing concentrations of retinoids alone, or in the presence of T-RA to determine the antagonistic potential of the ligands.

15        *Determination of NB4 cell differentiation.* NB4 cells were obtained from ATCC and were grown in RPMI-1640 (plus 2 mM L-glutamine) containing 100 units/microliter penicillin and streptomycin and 8% fetal bovine serum (FBS). Cells were treated for four days with retinoid(s) or ethanol vehicle, then washed and resuspended at a density of  $5 \times 10^5$  cells/ml. 50 microliter aliquots of this suspension were spread over poly-L-lysine coated slides (Sigma, St. Louis, Missouri). After washing with PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.4 mM KH<sub>2</sub>PO<sub>4</sub>), the cells were fixed for 10 minutes in 2% formalin (37% formaldehyde in 15% methanol  
20 in water) at room temperature.

25        *Nitroblue tetrazolium determination:* Following fixation, cells were washed three times in PBS and were scored by TPA (12-O-tetradecanoyl-phorbol-13-acetate, 200 ng/ml)-induced nitroblue tetrazolium reduction (Sigma Fast BCIP/NBT) for 30 minutes at 37°C. Samples were examined for cellular and nuclear morphology with an optical microscope (Diavert Leitz); the percentage of differentiated cells was determined by counting at least 300 cells for each treatment.

*Anti-PML immunofluorescence determination:* Following fixation, cells were permeabilized with 0.1% Triton X-100 in PBS (buffer A). After washing in PBS, the cells were blocked in 0.5 mg/ml normal goat IgG (Jackson Laboratories, Bar Harbor, Maine) in PBS for 30 minutes at room temperature, and thereafter incubated overnight at 4°C with a polyclonal anti-  
5 PML antibody (the kind gift of Dr. Anne Dejean), diluted in buffer A containing 0.5 mg/ml normal goat IgG (buffer B) at 4°C. After three washes in buffer A, the cells were incubated with donkey anti-rabbit IgG (H+L) conjugated with cyanine 3 (Jackson Laboratories, Bar Harbor, Maine) in buffer B for 1 hour at room temperature. Following washes in PBS the mounted samples were examined with a confocal laser microscope (TCS, Leica) equipped with cyanine optics for PML  
10 localization.

*Determination of NB4 cell apoptosis*

*Flow cytometric analysis.* The cell cycle distribution and presence of "sub-2N" cells and particles in control and retinoid-treated NB4 cells were determined by cell cycle flow cytometry based on DNA content, using an EPICS Profile II cell sorter (Coulter Electronics, Inc., Hialeah,  
15 Florida) equipped with a 15 watt argon laser tuned to an excitation wavelength of 488 nm and filter sets providing an emission wavelength of 575 nm. Cultures of untreated or retinoid-treated cells were centrifuged (250 x g) and fixed in 70% ethanol and stored at -20°C. Following two washes in PBS, the cells and subcellular particles were incubated in 1 mg/ml RNase A (59 Kunitz units/mg, Sigma Chemical Co., St. Louis, Missouri) for 30 minutes at 37°C, centrifuged and  
20 resuspended in PBS at a concentration of approximately 10<sup>6</sup> cells per ml. Ethidium bromide was added to a final concentration of 50 micrograms/ml immediately prior to sample analysis.

*DNA fragmentation analysis.* The induction of apoptosis by retinoids was also determined by the appearance of a "ladder" of fragmented DNA as previously described (Nagy, L., et al., *Mol. Cell. Biol.* 15:3540-3551 (1995)). Cells were refed with fresh media and retinoids every 2  
25 days, and the cell density was maintained well below saturation in order to prevent cell death due to nutrient and/or mitogen depletion. Five micrograms per lane of DNA was electrophoresed in a 1.5% agarose gel, followed by staining with ethidium bromide, and DNA bands were visualized and photographed via ultraviolet illumination of ethidium bromide fluorescence.

*In vivo RAR $\beta$ 2 footprinting and RAR $\beta$ ,  $\gamma$  expression.*

*Ligation-mediated PCR.* NB4 cells were cultured as described above. P19.6 cells were obtained from ATCC and were cultured in Dulbecco's modified Eagle's medium containing 5% normal FBS and 5% delipidated FBS. NB4 cells were treated with either ethanol or the indicated 5 retinoids (Figure 6) for 24 hours. After washing in PBS, the cells were treated with 0.1% dimethylsulfate (DMS; Aldrich) for 5 minutes at room temperature. High molecular weight DNA was extracted and cleaved with piperidine. DMS treatment *in vitro* of naked DNA was done as described (Mueller, P.R., and Wold, B., *Science* 246:780-786 (1989)). Ligation-mediated polymerase chain reaction (LM-PCR) was performed as described (Garrity, P.A., and Wold, B.J., 10 *Proc. Natl. Acad. Sci. USA* 89:1021-1025 (1992)), except that DEEPVENT™ (exo<sup>-</sup>) DNA polymerase (New England BioLabs, Beverly, Massachusetts) was used. Oligonucleotides used in LM-PCR to detect interactions on the coding strand were:

a.) Human RAR $\beta$ 2 promoter:

primer 1: 5'-CCCCCTTGGCAAAGAATAGAC-3' (SEQ ID NO:1)

15 primer 2: 5'-AGAATAGACCCTCCTGCCTCTGAAC-3' (SEQ ID NO:2)

primer 3: 5'-ACCCTCCTGCCTCTGAACAGCTCACTTC (SEQ ID NO:3)

b.) Mouse RAR $\beta$ 2 promoter:

primer 1: 5'-CCCCCTTGGCAAAGAATAGAC-3' (SEQ ID NO:1)

primer 2: 5'-AGAATAGACCCTCCTGCCTCGGAG-3' (SEQ ID NO:4)

20 primer 3: 5'-ACCCTCCTGCCTCGGAGCAGCTCACTT-3' (SEQ ID NO:5)

Each primer 3 (SEQ ID NOS: 3 and 5) was labeled at the 5' end with [ $\gamma$ -<sup>32</sup>P]ATP using T4 polynucleotide kinase. After PCR, labeled products were resolved in a 4.8% sequencing gel and gels were dried and exposed to X-ray film for production of autoradiograms.

*Reverse transcriptase PCR.* Total RNA was isolated and reverse transcribed in a buffer 25 solution comprising 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl<sub>2</sub> and 1 mM of all four deoxynucleoside triphosphates, using 25 units of AMV reverse transcriptase in the presence of 50 units of RNAsin for 60 minutes at 42°C. For reverse transcription, 25 picomoles per reaction of the common antisense primer 5'-GACATGCCACTTCAAAGCACTTC-3' (SEQ ID NO:6) for either RAR $\alpha$ ,  $\beta$  or  $\gamma$  was used. For each PCR reaction the common antisense primer, one- 30 fourth of the reverse transcribed product and the following specific sense primers were used:

human RAR $\alpha$ : 5'-ACCCCCTCTACCCCGCATCTACAAG-3' (SEQ ID NO:7)

human RAR $\beta$ : 5'-CTCGTCCCAAGCCCCCATCT-3' (SEQ ID NO:8)

human RAR $\gamma$ : 5'-ACAAGCCATGCTTCGTGTGCAAT-3' (SEQ ID NO:9)

The amplification was carried out in a final volume of 0.1 ml, using *Taq* DNA polymerase 5 (Perkin Elmer Cetus) according the manufacturer's instructions. Eighteen PCR cycles (30 seconds at 94°C, 30 seconds at 65°C and 30 seconds at 72°C) were performed, and a 10 microliter aliquot of each reaction was analyzed by electrophoresis on a 6% native polyacrylamide gel, which was then stained with ethidium bromide and examined by ultraviolet illumination.

***Example 1: RAR- and RXR-induced Activation***

10 Receptor-selective synthetic retinoids (Chen, J.-Y., *et al.*, *EMBO J.* 14:1187-1197 (1995)) (FIG. 1) were used to investigate the contributions of RAR $\alpha$ /PML-RAR $\alpha$ , RAR $\beta$ , RAR $\gamma$  and RXRs to the molecular and cellular events which lead to NB4 (Lanotte, M., *et al.*, *Blood* 77:1080-1086 (1991)) cell differentiation upon T-RA treatment. As shown in Table 1, the agonist Am80, which is RAR $\alpha$ -specific at  $\leq$  1nM (Chen, J.-Y., *et al.*, *EMBO J.* 14:1187-1197 (1995)), 15 efficiently induced differentiation. Retinoids lacking RAR $\alpha$  agonistic activity (Compound A and Compound C; Chen, J.-Y., *et al.*, *EMBO J.* 14:1187-1197 (1995)); Compound B and Compound D, FIG. 1; SR11237 (Lehmann, J.M., *et al.*, *Science* 258:1944-1946 (1992)), were ineffective on their own (Table 1, FIGs. 3b, c). Compound C is the compound described in Example 23 of European Patent Application No. EP 0 661 259, which is incorporated by reference herein in its 20 entirety. Compound D is the compound described in Example 1 of European Patent Application No. EP 0 747 347, which is incorporated by reference herein in its entirety. Moreover, the differentiation induced by 1 nM Am80 was completely blocked by an excess of Compound B, a pure RAR $\alpha$  antagonist (not shown). These results demonstrate that inducing the transcriptional activity of AF-2 of either the non-fused RAR $\alpha$  allele and/or the RAR $\alpha$  moiety of PML-RAR $\alpha$  is 25 sufficient to relieve the differentiation block resulting from the formation of a PML-RAR $\alpha$  fusion protein. Note that AP1 transrepression by RAR $\alpha$  is unlikely to play a critical role in RA-induced NB4 cell differentiation, since "dissociated" retinoids, such as Compound A, albeit efficiently

repressing AP1 activity via all three RARs (Chen, J-Y, *et al.*, *EMBO J.* 14:1187-1197 (1995)), did not induce differentiation on their own (FIG. 2b, and not shown).

After 4 days of treatment with T-RA or RAR $\alpha$  agonists, FACS analysis showed that NB4 cells had reduced mitotic activity and accumulated in G1/G0 (FIGs. 4b and e). At day 6, sub-2N particles accumulated in T-RA-treated cultures (FIG. 4c) and at day 8 massive DNA fragmentation indicated extensive apoptosis (FIGs. 4d, f, and FIG. 5, lanes 6, 7). Note that forward and side scatter analysis of the same cell preparations confirmed these results (not shown). As in the case of differentiation, only RAR $\alpha$  (but not RAR $\beta$  or RAR $\gamma$ ) agonists could induce this sequence of events (Table 1, and not shown).

Prior to differentiation, and as previously reported (Dyck, J.A., *et al.*, *Cell* 76:333-343 (1994); Weis, K., *et al.*, *Cell* 76:345-358 (1994); Koken, M.H., *et al.*, *EMBO J.* 13:1073-1083 (1994)) for T-RA, RAR $\alpha$  agonists induced the association of endogenous PML/PML-RAR $\alpha$  with nuclear bodies (FIG. 3e), while RAR $\alpha$  antagonists did not (FIG. 3f, and data not shown). Moreover, *in vivo* DNA footprinting showed that occupation of the DR5-type retinoic acid response elements (DR5-RAREs) present in the RAR $\beta$ 2 promoter, as well as the recruitment of other promoter-binding factors, was induced by RAR $\alpha$  agonists, but not antagonists (FIG. 5, lanes 3, 5 and 6). Apart from minor differences, these footprints were nearly indistinguishable from those originally reported for mouse P19 embryonal carcinoma cells (Dey, A., *et al.*, *Mol. Cell. Biol.* 14:8191-8201 (1994)) (FIG. 6b, lanes 3, 6, 7). The Am80-induced expression of RAR $\beta$ 2 (and RAR $\gamma$ ) was confirmed by RT-PCR (not shown); no induction was seen with RAR $\alpha$  antagonists alone (Compound A in FIG. 6c, and not shown).

-31-

		Percentage of NB4 cells differentiated						+100 nM SR 11237			
Retinoid (nM)	T-RA	9C-RA	Am80	Compound A	Compound B	Compound C	Compound D	SR11237	Am80	Compound A	Compound B
0.1	- <sup>1</sup>	-	<1	-	-	-	-	-	<1	-	-
0.3	-	-	<1	-	-	-	-	-	20	-	-
0.5	-	-	<1	-	-	-	-	-	40	-	-
5	1	<1	<1	80	-	-	-	-	80	<1	<1
10	<1	4	81	-	-	-	-	-	-	65	3
100	81	65	80	-	-	-	-	-	-	78	5
1000	80	70	-	<1	<1	<1	<2	-	-	-	10

<sup>1n - n</sup> = not done.

**Example 2: Synergism Between RAR- and RXR-specific Ligands**

The possible role of RXR in the above events, beyond that of a mere partner for heterodimerization, was investigated by analyzing whether RAR- and RXR-specific ligands could synergize. Indeed, in the presence of the RXR-specific agonist SR11237, Am80 was significantly 5 more efficient at inducing differentiation at low concentrations (Table 1; note that SR11237 alone did not induce differentiation; FIG. 3c). Strikingly and unexpectedly, in combination with SR11237 even the RAR $\alpha$  antagonist Compound A induced differentiation with higher efficiency than T-RA or 9C-RA (Table 1; FIG. 3d). It is unlikely that this differentiation could be due to autoinduction of RAR $\beta$ 2 by the RAR $\beta$ -agonistic activity (FIG. 1) of Compound A in the presence 10 of SR11237, since Compound C (FIG. 1), a stronger RAR $\beta$  agonist than Compound A (Chen, J-Y, *et al.*, *EMBO J.* 14:1187-1197 (1995)), did not synergize with SR11237 to induce RAR $\beta$ 2-promoter occupancy (FIG. 6a, b), RAR $\beta$ 2 mRNA production or differentiation (not shown). In addition, Compound B, a "pure" RAR $\alpha$  antagonist which does not bind RAR $\beta$  or RAR $\gamma$  (FIG. 1), also induced differentiation in presence of SR11237, while the RAR $\gamma$ ( $\beta$ ) agonist Compound 15 D, which cannot bind RAR $\alpha$ , did not (Table 1 and not shown). The lower efficiency of Compound B relative to Compound A may be related to its lower binding affinity for RAR $\alpha$  (FIG 2, and not shown).

Together the above results clearly indicate that RAR $\alpha$  (or PML-RAR $\alpha$ ) is specifically involved in the synergistic induction of differentiation in presence of the RXR agonist. Synergy 20 between RAR $\alpha$  and RXR ligands was not only observed for differentiation, but also for subsequent apoptosis. This was demonstrated by the strong antiproliferative and apoptotic effect of a combination of the RAR $\alpha$  antagonist Compound A together with the RXR agonist SR11237, each of which was inefficient alone (FIGs. 4g and h, FIG. 5; and forward and side scatter analysis, not shown). Compound A/SR11237-induced differentiation and apoptosis was preceded by an 25 association of PML-RAR $\alpha$  with nuclear bodies which was indistinguishable from that seen in presence of RAR $\alpha$  agonists (FIG. 3g and h). Moreover, occupation of the RAR $\beta$ 2 RARE and factor recruitment (Dey, A., *et al.*, *Mol. Cell. Biol.* 14:8191-8201 (1994)) to the RAR $\beta$ 2 promoter *in vivo* was also induced when cells were treated with Compound A and SR11237 (FIG 6a). This treatment led to an efficient accumulation of RAR $\beta$  and RAR $\gamma$  mRNA (FIG. 6c). In

keeping with its inability to synergize with SR11237 for differentiation, the other RAR $\alpha$  antagonist/RAR $\beta$  agonist Compound C was neither able to induce nuclear body association of PML-RAR $\alpha$  (not shown) nor RAR $\beta$ 2 promoter occupancy (FIG. 6a).

### ***General Discussion***

5 It has previously been suggested that the RXR ligand-dependent transcription activation function AF-2 is silent in RAR-RXR receptor heterodimeric signaling complexes (Kurokawa, R., *et al.*, *Nature* 371:528-531 (1994); Forman, B.M., *et al.*, *Cell* 81:541-550 (1995); Mangelsdorf, D.J., and Evans, R.M., *Cell* 83:835-850 (1995)). In contrast, the present results demonstrate that in cultured NB4 human acute promyelocytic leukemia (APL) cells, *in vivo* footprints of the  
10 RAR $\beta$ 2 promoter RA response element and RAR $\beta$ 2 mRNA expression can be induced not only by treatment with RAR $\alpha$ - (and not RAR $\beta$ -, RAR $\gamma$ - or RXR-) specific retinoids alone, but also by the combination of certain RAR $\alpha$  antagonists with a pure RXR agonist. Moreover, such combinations induce the relocation of PML to nuclear bodies and NB4 cell differentiation prior to apoptosis. These results indicate that the effects exerted by retinoids on APL cells are  
15 mediated by heterodimers between RAR $\alpha$  (or PML-RAR $\alpha$  and RXRs), in which the AF-2 of only one partner needs to be transcriptionally competent. Thus, RAR $\alpha$  agonists induce two separable events. One event that is required for binding of RXR-RAR $\alpha$  heterodimers to DNA *in vivo* and allows the RXR AF-2 to be activated by agonists can be induced by either a RAR $\alpha$  agonist or certain RAR $\alpha$  antagonists, whereas the other event which induces RAR $\alpha$  AF-2 activity can be  
20 exerted by RAR $\alpha$  agonists only.

The synergism between RAR and RXR ligands is difficult to reconcile with the conclusion of previous reports (Kurokawa, R., *et al.*, *Nature* 371:528-531 (1994); Forman, B.M., *et al.*, *Cell* 81:541-550 (1995)) that RXR is a transcriptionally silent partner in RXR-RAR heterodimers on both DR1 and DR5 RAREs (reviewed in Mangelsdorf, D.J. and Evans, R.M., *Cell* 83:835-850  
25 (1995)). Specifically, how could a heterodimer comprising an antagonist-bound RAR $\alpha$  and an agonist-bound RXR bind to and activate transcription from the RAR $\beta$ 2 promoter, if RXR were unable to bind its ligand when associated with DNA? In fact, one of the above reports (Forman, B.M., *et al.*, *Cell* 81:541-550 (1995)) distinguishes between the inhibitory effects of ligand-free

and ligand-bound RAR on RXR activity. Moreover, in contrast to the above reports (Kurokawa, R., *et al.*, *Nature* 371:528-531 (1994); Forman, B.M., *et al.*, *Cell* 81:541-550 (1995)), more recent studies (Kersten, S., *et al.*, *Biochemistry* 35:3816-3824 (1996); Apfel, R., *et al.*, *J. Biol. Chem.* 270:30765-30772 (1995)) have concluded that both partners of RXR-RAR heterodimers bind their cognate ligand irrespective of their binding to DNA, thus supporting the previous conclusion drawn from transfection experiments that both partners can be transcriptionally active (Durand, B., *et al.*, *Cell* 71:73-85 (1992)). Regardless of what may be the basis of the conflicting *in vitro* results, it is clear that *in vivo* the RXR partner of RXR-RAR dimers can respond to an agonistic ligand and, therefore, must bind it. In keeping with this conclusion, *in vivo* synergism between RAR and RXR agonists has been previously reported (Roy, B., *et al.*, *Mol. Cell. Biol.* 15:6481-6487 (1995); Apfel, R., *et al.*, *J. Biol. Chem.* 270:30765-30772 (1995)).

The present studies show that, at high levels, RAR agonists alone are sufficient to induce the genetic programs leading to differentiation and apoptosis of NB4 cells, as well as transcription from the RAR $\beta$ 2 promoter. In contrast, a RXR agonist was inactive unless it is associated with a RAR agonist or certain RAR antagonists. It appears therefore that (i) the apo-RAR structure in the RXR-RAR heterodimer is incompatible with events which are requisite to transactivation *in vivo*, and (ii) transactivation by RXR-RAR heterodimer comprises two separable RAR-mediated events. One event that is required for binding of RXR/RAR $\alpha$  heterodimers to DNA *in vivo* and allows the RXR AF-2 to be activated by agonists, can be induced by either a RAR $\alpha$  agonist or certain RAR $\alpha$  antagonists. The other event induces RAR $\alpha$  AF-2 activity and can be exerted by RAR $\alpha$  agonists only.

Upon extension of the present results to other RA target genes, the conclusion that one of the two functions exerted by RAR ligands in RXR-RAR heterodimers is requisite for RXR ligands to activate target gene transcription *in vivo* has important implications. RARs will "dominate" over their RXR partners and the presence of RXR agonists would amplify the effect of, but not substitute for, RAR ligands. Note in this respect that the RXR-specific ligand SR11237 on its own was unable to induce the differentiation and expression of RA target genes in F9 and P19 cells (Roy, B., *et al.*, *Mol. Cell. Biol.* 15:6481-6487 (1995)). The same may be true for RXR heterodimer-mediated signaling pathways involving thyroid hormones and vitamin D3, while for other RXR heterodimers (Mangelsdorf, D.J. and Evans, R.M., *Cell* 83:835-850

(1995)) RXR ligands may act as independent signaling molecules. The design and study of additional RAR and RXR agonists and antagonists by the methods disclosed herein will indicate whether this concept of "dominance" of RAR over RXR can be generalized, and to what extent other synthetic ligands could overcome or modify this "dominance."

5        Neither RAR $\alpha$  specificity nor the synergism between RAR $\alpha$ /Compound A and RXR/SR11237 are NB4 cell- or PML-RAR $\alpha$ -specific. Human HL-60 myeloblastic leukemia cells lacking the PML-RAR $\alpha$  fusion protein responded like NB4 cells to the various ligand combinations with respect to RAR $\beta$ 2 promoter occupancy, RAR $\beta$ 2 mRNA accumulation and differentiation (not shown). However, it has been reported that, in contrast to NB4 cells,  
10      apoptosis of HL-60 cells cannot be achieved with a RAR agonist only, and specifically requires the presence of a RXR agonist (Nagy, L., *et al.*, *Mol. Cell. Biol.* 15:3540-3551 (1995)). RAR $\beta$ 2 promoter occupancy and RAR $\beta$ 2 mRNA accumulation was also observed in P19 embryonal carcinoma (EC) cells treated with a combination of a RAR $\alpha$  antagonist and a RXR agonist (Roy, B., *et al.*, *Mol. Cell. Biol.* 15:6481-6487 (1995)) (FIG. 3b). In marked contrast, in F9 EC cells  
15      the same ligand combination induced neither RAR $\beta$ 2 expression nor differentiation (data not shown). Thus, taken together with the ability of "dissociated" retinoids (Chen, J.-Y., *et al.*, *EMBO J.* 14:1187-1197 (1995)) to repress AP1 activity, the present results suggest that it may be possible to initiate complex gene programs in a cell-specific manner by the appropriate choice of (or combination of) synthetic retinoids with predefined characteristics. The selectivity and the  
20      synergistic potential of RAR and RXR ligands, which allow drastically reduced concentrations of the individual compounds to achieve biological activity, have considerable promise for extending the therapeutic applications of natural and synthetic retinoids and retinoid analogues.

Having now fully described the present invention in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious to one of ordinary skill in the  
25      art that the same can be performed by modifying or changing the invention within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any specific embodiment thereof, and that such modifications or changes are intended to be encompassed within the scope of the appended claims.

-36-

All publications, patents and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains, and are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference.

-37-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Institut National de la Santé et de la Recherche Médical
- (B) STREET: 101 Rue Tolbiac
- (C) CITY: Paris Cedex 13
- (D) STATE:
- (E) COUNTRY: France
- (F) POSTAL CODE (ZIP): 75654

(i) APPLICANT:

- (A) NAME: Centre National de la Recherche Scientifique
- (B) STREET: 3 Rue Michel Ange
- (C) CITY: Paris Cedex 16
- (D) STATE:
- (E) COUNTRY: France
- (F) POSTAL CODE (ZIP): 75794

(i) APPLICANT:

- (A) NAME: Université Louis Pasteur
- (B) STREET: 4 Rue Blaise Pascal
- (C) CITY: Strasbourg Cedex
- (D) STATE:
- (E) COUNTRY: France
- (F) POSTAL CODE (ZIP): 67070

(i) APPLICANT:

- (A) NAME: Bristol-Myers Squibb Company
- (B) STREET: Route 206 & Provinceline Road
- (C) CITY: Princeton
- (D) STATE: New Jersey
- (E) COUNTRY: USA
- (F) POSTAL CODE (ZIP): 08543-4000

(i) INVENTOR:

- (A) NAME: Pierre Chambon
- (B) STREET: 4 Rue A. Schweitzer
- (C) CITY: Blaesheim
- (D) STATE:

-38-

(E) COUNTRY: France  
(F) POSTAL CODE (ZIP): 67113

(i) INVENTOR:  
(A) NAME: Hinrich Gronemeyer  
(B) STREET: 1A Uhlandstrasse  
(C) CITY: Oberkirch  
(D) STATE:  
(E) COUNTRY: Germany  
(F) POSTAL CODE (ZIP): 77704

(i) INVENTOR:  
(A) NAME: Peter R. Reczek  
(B) STREET: 100 Forest Avenue, Department 842  
(C) CITY: Buffalo  
(D) STATE: New York  
(E) COUNTRY: USA  
(F) POSTAL CODE (ZIP): 14213-1091

(i) INVENTOR:  
(A) NAME: Jacek Ostrowski  
(B) STREET: 100 Forest Avenue, Department 842  
(C) CITY: Buffalo  
(D) STATE: New York  
(E) COUNTRY: USA  
(F) POSTAL CODE (ZIP): 14213-1091

(ii) TITLE OF INVENTION: Therapeutic Combinations of RAR  
Antagonists and RXR Agonists and Use Thereof

(iii) NUMBER OF SEQUENCES: 9

(iv) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:  
(A) APPLICATION NUMBER: US 60/024,772  
(B) FILING DATE: 28-AUG-1996

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

-39-

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCCCCTTG CAAAGAATAG AC

22

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AGAATAGACC CTCCTGCCTC TGAAC

25

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ACCCTCCTGC CTCTGAAACAG CTCACTTC

28

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

-40-

AGAATAGACC CTCCTGCCTC GGAG

24

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ACCCTCCTGC CTCGGAGCAG CTCACTT

27

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GACATGCCCA CTTCAAAGCA CTTC

24

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ACCCCTCTA CCCCGCATCT ACAAG

25

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

-41-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTCGTCCCAA GCCCCCATC T

21

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ACAAGCCATG CTTCGTGTGC AAT

23

**WHAT IS CLAIMED IS:**

1. A method for treating an animal suffering from or predisposed to a physical disorder, said method comprising administering to said animal an effective amount of a composition comprising at least one RAR antagonist and at least one RXR agonist.  
5
2. The method of claim 1, wherein said RAR antagonist is a RAR $\alpha$  antagonist.
3. The method of claim 8, wherein said RAR $\alpha$  antagonist is Compound A or Compound B.  
10
4. The method of claim 1 wherein said RXR agonist is SR11237.
5. A pharmaceutical composition comprising at least one RAR antagonist, at least one RXR agonist and a pharmaceutically acceptable carrier or excipient therefor.  
15
6. The composition of claim 5, wherein said RAR antagonist is an RAR $\alpha$  antagonist.  
7. The composition of claim 6, wherein said RAR $\alpha$  antagonist is Compound A or Compound B.  
8. The composition of claim 5, wherein said RXR agonist is SR11237.

9. A method for treating an animal that is suffering from or is predisposed to a physical disorder comprising administering to said animal the pharmaceutical composition of any one of claims 5-8.

10. The method of claim 1 or claim 9, wherein said disorder is selected  
5 from the group consisting of a cancer, a skin disorder, rheumatoid arthritis and a premalignant lesion.

11. The method of claim 10, wherein said cancer is selected from the  
group consisting of a skin cancer, an oral cavity cancer, a lung cancer, a mammary  
10 gland cancer, a prostatic cancer, a bladder cancer, a liver cancer, a pancreatic  
cancer, a cervical cancer, an ovarian cancer, a head and neck cancer, a colon  
cancer, a germ cell cancer and a leukemia.

12. The method of claim 11, wherein said skin cancer is a melanoma  
or Kaposi's sarcoma.

13. The method of claim 11, wherein said germ cell cancer is a  
15 teratocarcinoma.

14. The method of claim 11, wherein said leukemia is acute  
promyelocytic leukemia.

15. The method of claim 10, wherein said skin disorder is selected from  
the group consisting of psoriasis, actinic keratosis, acne, ichthyosis, photoaging  
20 and corticosteroid-induced skin atrophy.

16. The method of claim 1 or claim 9, wherein said animal is a human.

Retinoid	RAR		
	$\alpha$	$\beta$	$\gamma$
Compound A	-	+	-
Compound B	-	o	o
Compound C	-	+	(+)
Compound D	o	(+)	+

Fig. I




FIGURE 2.

3/6




FIGURE 3




FIGURE 4.

5/6




FIGURE 5





FIGURE 6.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  A61K 45/06	A3	(11) International Publication Number: <b>WO 98/08546</b>
		(43) International Publication Date: 5 March 1998 (05.03.98)
(21) International Application Number: PCT/US97/15155		(74) Agents: STEFFE, Eric, K. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue N.W., Washington, DC 20005-3934 (US).
(22) International Filing Date: 28 August 1997 (28.08.97)		
(30) Priority Data: 60/024,772 28 August 1996 (28.08.96) US		(81) Designated States: AU, CA, IL, JP, MX, NO, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
<p><b>(71) Applicants:</b> INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE [FR/FR]; 101, rue Tolbiac, F-75654 Paris Cedex (FR). CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3, rue Michel Ange, F-75794 Paris Cedex 16 (FR). UNIVERSITE LOUIS PASTEUR [FR/FR]; 4, rue Blaise Pascal, Boite postale 1032F, F-67070 Strasbourg Cedex (FR). BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206, Provinceline Road, Princeton, NJ 08543-4000 (US).</p> <p><b>(72) Inventors:</b> CHAMBON, Pierre; 4, rue A. Schweitzer, F-67113 Blaesheim (FR). GRONEMEYER, Hinrich; Uhlandstrasse 1A, D-77704 Oberkirch (DE). RECZEK, Peter, R.; Dept. 842, 100 Forest Avenue, Buffalo, NY 14213-1091 (US). OSTROWSKI, Jacek; Dept. 842, 100 Forest Avenue, Buffalo, NY 14213-1091 (US).</p>		

(54) Title: THERAPEUTIC COMBINATIONS OF RAR ANTAGONISTS AND RXR AGONISTS



## (57) Abstract

The present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder by administering an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR $\alpha$  antagonist, and at least one RXR agonist. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

# INTERNATIONAL SEARCH REPORT

Internat'l Application No  
PCT/US 97/15155

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6 A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BROOKS S C III ET AL: "Myeloid differentiation and retinoblastoma phosphorylation changes in HL-60 cells induced by retinoic acid receptor- and retinoid X receptor-selective retinoic acid analogs"  <i>BLOOD</i>, 87 (1). 01-01-1996. 227-237,  XP000572287  see page 233, column 2, paragraph 2 - page 236, column 1, paragraph 2</p> <p>---</p>	1-16
X,P	<p>CHEN J-Y ET AL: "Two distinct actions of retinoid-receptor ligands"  <i>NATURE (LONDON)</i>, 382 (6594). 29-08-1996.  819-822., XP002051445  see abstract</p> <p>---</p> <p>-/-</p>	1-16

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

2

Date of the actual completion of the international search	Date of mailing of the international search report
12 January 1998	12.02.98
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax (+31-70) 340-3016	Leherte, C

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/15155

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HEMBREE J R ET AL: "Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor-specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells" CANCER RESEARCH, 56 (8). 15-04-1996. 1794-1799., XP002051446 see page 1798, column 1, paragraph 4 - page 1798, column 2, paragraph 2 -----	1-16

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/15155

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 1-4, 9-16 because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-4, 9-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.